Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.85 |
| ▸ | KDR | P35968 | 2/20 | 0.84 |
| ▸ | AURKA | O14965 | 1/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.84 |
| ▸ | INSR | P06213 | 1/20 | 0.84 |
| ▸ | FBP1 | P09467 | 1/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.84 |
| ▸ | FLT4 | P35916 | 1/20 | 0.84 |
| ▸ | CLK1 | P49759 | 1/20 | 0.84 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.84 |
| ▸ | TEK | Q02763 | 1/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207668 | 1.00 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL28520911 | 1.00 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL31491085 | 1.00 | EGFR (0.85) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL5412843 | 0.96 | EGFR (0.84) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL28907231 | 0.96 | EGFR (0.84) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL29577315 | 0.95 | FBP1 (0.78) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL14092460 | 0.94 | EGFR (0.92) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL13529196 | 0.93 | EGFR (0.98) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL5911655 | 0.93 | EGFR (0.86) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL30520472 | 0.93 | EGFR (0.87) | EGFRKDRAURKAERBB2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-03 | — | — | US | disclosed |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-03 | — | — | US | disclosed |
| CN-117903068-A | Preparation method of gefitinib | 山东新时代药业有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| CN-115611910-A | Preparation method of aminoquinazoline compound | 广东东阳光药业有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| EP-2796451-A1 | HETEROCYCLE AMIDO ALKYLOXY SUBSTITUTED QUINAZOLINE DERIVATIVE AND USE THEREOF | Qian, Wei (CN) | 2014-10-29 | — | — | EP | disclosed |
| EP-2780342-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140206664-A1 | Heterocycle Amido Alkyloxy Substituted Quinazoline Derivative and Use Thereof | QIAN WEI (CN) | 2014-07-24 | — | — | US | disclosed |
| US-20140206664-A1 | Heterocycle Amido Alkyloxy Substituted Quinazoline Derivative and Use Thereof | QIAN WEI (CN) | 2014-07-24 | — | — | US | disclosed |
| WO-2013091507-A1 | HETEROCYCLE AMIDO ALKYLOXY SUBSTITUTED QUINAZOLINE DERIVATIVE AND USE THEREOF | QIAN WEI (CN) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | EGFR 460/4885KDR 949/4885AURKA 785/4885 |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | EGFR 3726/4885KDR 2930/4885AURKA 2892/4885 |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | EGFR 2717/4885KDR 1193/4885AURKA 4564/4885 |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | SERPINA6, SELPLG, FABP7 | EGFR 3638/4885KDR 2741/4885AURKA 3466/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDR 112/4885AURKA 1570/4885 |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | CCRL2, CFB, CCR3 | EGFR 1974/4885KDR 876/4885AURKA 4409/4885 |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDR 35/4885AURKA 2027/4885 |
| US-20140206664-A1 | Heterocycle Amido Alkyloxy Substituted Quinazoline Derivative and Use Thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 96/4885AURKA 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.